Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 6
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
6| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10953003 | XOLREMDImavorixafor | product | Dec 2036 |
| 10610527 | XOLREMDImavorixafor | use | Dec 2036 |
| 11219621 | XOLREMDImavorixafor | use | Dec 2036 |
| 10548889 | XOLREMDImavorixafor | product | Dec 2038 |
| 11045461 | XOLREMDImavorixafor | product | Dec 2038 |
| 12115156 | XOLREMDImavorixafor | product | Dec 2038 |
| Product | Exclusivity | Until |
|---|---|---|
| XOLREMDIMAVORIXAFOR | ODE-480 Orphan drug | Apr 2031 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| XOLREMDI | mavorixafor | capsule, gelatin coated, oral | 83296-100NDA |
Enquiry
Common questions
- Is X4 Pharmaceuticals, Inc. FDA approved?
- X4 Pharmaceuticals, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does X4 Pharmaceuticals, Inc. make?
- 1 product is listed under X4 Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as capsule, gelatin coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.